I

n a win for the pharmaceutical industry, the Food and Drug Administration has indefinitely delayed implementing a final rule that would give the agency greater leeway to police off-label marketing.

This marks the second time in the past year the agency has delayed the rule, which was scheduled to go into effect in March, and follows alarm expressed by drug makers that the proposed rule would harm public health and chill “valuable scientific speech.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that Commissioner Scott G may be picking his battles – may be, of course is the operative phrase. once again, time will tell.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X